211 related articles for article (PubMed ID: 16148164)
1. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
Straathof KC; Leen AM; Buza EL; Taylor G; Huls MH; Heslop HE; Rooney CM; Bollard CM
J Immunol; 2005 Sep; 175(6):4137-47. PubMed ID: 16148164
[TBL] [Abstract][Full Text] [Related]
2. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
4. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
5. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
8. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
[TBL] [Abstract][Full Text] [Related]
9. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
[TBL] [Abstract][Full Text] [Related]
10. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
11. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
[TBL] [Abstract][Full Text] [Related]
12. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
[TBL] [Abstract][Full Text] [Related]
13. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.
Khanna R; Burrows SR; Moss DJ; Silins SL
J Virol; 1996 Aug; 70(8):5357-62. PubMed ID: 8764046
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
15. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
[TBL] [Abstract][Full Text] [Related]
16. Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.
Lu XL; Liang ZH; Zhang CE; Lu SJ; Weng XF; Wu XW
Acta Biochim Biophys Sin (Shanghai); 2006 Mar; 38(3):157-63. PubMed ID: 16518539
[TBL] [Abstract][Full Text] [Related]
17. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
18. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.
Jurgens LA; Khanna R; Weber J; Orentas RJ
J Clin Immunol; 2006 Jan; 26(1):22-32. PubMed ID: 16418800
[TBL] [Abstract][Full Text] [Related]
19. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine.
Duraiswamy J; Bharadwaj M; Tellam J; Connolly G; Cooper L; Moss D; Thomson S; Yotnda P; Khanna R
Cancer Res; 2004 Feb; 64(4):1483-9. PubMed ID: 14973049
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
